Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06842498 · ClinicalTrials.gov registry record · Phase 2

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

A Phase 2 study of Metastatic Castration-Resistant Prostate Cancer, sponsored by Kyntra Bio.

Recruiting
Registry status
Phase 2
Development phase
75
Enrollment target
15
Study locations

NCT06842498 is a Phase 2 study of Metastatic Castration-Resistant Prostate Cancer that is actively recruiting participants, run by Kyntra Bio. The registered enrollment target is 75 participants, below the 197-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (62% lower). The trial reports 15 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06842498, a Phase 2 study of Metastatic Castration-Resistant Prostate Cancer, is actively recruiting participants, sponsored by Kyntra Bio.

RECRUITING
Registry status
Phase 2
Development phase
75 participants
Enrollment target
15
Study locations

Study Summary

The purpose of this study is to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of FG-3246, a cluster of differentiation 46 (CD46) targeting antibody-drug conjugate (ADC), in the treatment of participants with mCRPC who have progressed following treatment with one prior second-generation androgen receptor signaling inhibitor (ARSI) in any setting and no prior taxane therapy in the mCRPC setting.

Conditions Studied

Metastatic Castration-Resistant Prostate Cancer

Interventions

  • DRUG FG-3246

Study Locations (15)

California

  • UCLA Clark Urology Center - Los Angeles
  • University of California San Francisco - San Francisco

Florida

  • Bioresearch Partner - Aventura
  • Bioresearch Partner - Hialeah

North Carolina

  • UNC Hospitals, The University of North Carolina at Chapel Hill - Chapel Hill
  • Duke University Medical Center - Duke Cancer Center - Durham

Texas

  • University of Texas Southwestern Medical Center - Dallas
  • Oncology Consultants - Houston

Arizona

  • The University of Arizona Cancer Center - North Campus - Tucson

Georgia

  • Winship Cancer Institute, Emory University - Atlanta

New Mexico

  • New Mexico Oncology Hematology Consultants, Ltd. - Albuquerque

Ohio

  • University Hospitals Cleveland Medical Center - Cleveland

Trial Details

FieldValue
Enrollment Target 75 participants
Start Date 2026-02-22
Est. Completion 2028-03-31
Phase Phase 2

Sponsor

Kyntra Bio

30 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06842498

The ClinicalTrials.gov registry entry for NCT06842498 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 197-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (62% lower). The listed sponsor is Kyntra Bio, which has 30 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Metastatic Castration-Resistant Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which FG-3246 is the first listed.

NCT06842498 reports 15 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, North Carolina.

Frequently Asked Questions

What is clinical trial NCT06842498 about?

NCT06842498 is a clinical study titled "A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)". The purpose of this study is to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of FG-3246, a cluster of differentiation 46 (CD46) targeting antibody-drug conjugate (ADC), in the treatment of participants with mCRPC who have progressed following treatment with one prior second...

What is the current status of trial NCT06842498?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2026-02-22. Estimated completion is 2028-03-31.

What conditions does trial NCT06842498 study?

This clinical trial studies the following conditions: Metastatic Castration-Resistant Prostate Cancer.

What interventions are being tested in trial NCT06842498?

The interventions under investigation include: FG-3246 (DRUG).

Who is sponsoring clinical trial NCT06842498?

This trial is sponsored by Kyntra Bio, which has 30 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06842498 being conducted?

This trial has 15 study locations across Arizona, California, Florida, Georgia, New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Castration-Resistant Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Castration-Resistant Prostate Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.